Cancer News, Research & Analysis
Time-sensitive and reliable coverage of pharmaceutical industry
developments, clinical trials, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €750/£675 a year per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna head office, Austria, European Union: +43 (0)1 71 71 8 900
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients
Patients can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. The clinical meaning of lymphovascular invasion: preoperative predictors and postoperative implications in prostate cancer - a retrospective study
- 2. Studies Indicate Environmental Factors Can Impact Urologic Health
- 3. Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
- 4. Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery
- 5. Lucem Health rolls out new AI-powered lung cancer screening solution
- 6. Novartis to Acquire Mariana Oncology for $1B Upfront
- 7. Personalized mRNA vaccines: A new approach in melanoma treatment
- 8. New global care standards to help those living with advanced cancer
- 9. Lymphocytes recruit the immune system to fight most aggressive breast cancer, study confirms
- 10. The key role of Galectin-3 in brain tumor development
Last updated at 17:57 GMT
Hot News Makers
Health/Pharma Companies
-
12085.81
-
2815.52
-
1123.83
-
992.53
-
910.22
-
825.40
-
747.40
-
737.18
-
725.86
-
679.45
Last updated at 17:10 GMT